Lipocine Inc. (NASDAQ:LPCN) – Research analysts at Zacks Investment Research issued their FY2021 earnings estimates for shares of Lipocine in a research note issued to investors on Tuesday, May 11th. Zacks Investment Research analyst J. Vandermosten forecasts that the specialty pharmaceutical company will earn ($0.21) per share for the year. Zacks Investment Research also issued estimates for Lipocine’s FY2022 earnings at $1.09 EPS and FY2023 earnings at $1.29 EPS.
Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Thursday, May 6th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01.
Lipocine stock opened at $1.30 on Friday. The company has a market capitalization of $114.78 million, a P/E ratio of -2.95 and a beta of 0.75. The firm’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.55. The company has a current ratio of 4.27, a quick ratio of 4.27 and a debt-to-equity ratio of 0.22. Lipocine has a 1-year low of $0.72 and a 1-year high of $2.42.
A number of institutional investors and hedge funds have recently made changes to their positions in LPCN. Kestra Advisory Services LLC bought a new position in Lipocine in the 4th quarter worth $453,000. GSA Capital Partners LLP raised its holdings in Lipocine by 133.0% in the 4th quarter. GSA Capital Partners LLP now owns 185,992 shares of the specialty pharmaceutical company’s stock worth $253,000 after acquiring an additional 106,175 shares during the period. BlackRock Inc. raised its holdings in Lipocine by 0.5% in the 4th quarter. BlackRock Inc. now owns 1,618,913 shares of the specialty pharmaceutical company’s stock worth $2,201,000 after acquiring an additional 8,212 shares during the period. Bank of New York Mellon Corp acquired a new stake in Lipocine in the 4th quarter worth $83,000. Finally, Northern Trust Corp grew its position in Lipocine by 40.4% in the 4th quarter. Northern Trust Corp now owns 124,210 shares of the specialty pharmaceutical company’s stock worth $169,000 after purchasing an additional 35,730 shares during the last quarter. Hedge funds and other institutional investors own 10.87% of the company’s stock.
Lipocine Inc, a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Read More: Options Trading
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.